Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is a publicly traded Healthcare sector company. As of July 8, 2026, ARQT trades at $27.66 with a market cap of $3.26B and a P/E ratio of -919.50. ARQT moved -0.76% today. Year to date, ARQT is -1.46%; over the trailing twelve months it is +106.65%. Its 52-week range spans $8.90 to $31.77. Analyst consensus is strong buy with an average price target of $34.83. Rallies surfaces ARQT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for ARQT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $27.66 |
| Market Cap | $3.26B |
| P/E Ratio | -919.50 |
| EPS | $-0.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.77 |
| 52-Week Low | $8.90 |
| Volume | 488.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $415.62M |
| Net Income | $-2.38M |
| Gross Margin | 90.94% |
6 analysts cover ARQT: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.83.